AZN vs NVS
Astrazeneca PLC and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | AZN | NVS |
|---|---|---|
| Revenue | $58.7B | $54.5B |
| Net income | $10.2B | $14.0B |
| Gross margin | 81.9% | 78.8% |
| Net margin | 17.4% | 25.6% |
| Return on equity | 22.9% | 31.0% |
| Diluted EPS | $6.54 | $7.15 |
| Dividend / share | $3.13 | — |
| Payout ratio | 48.6% | — |
| Free cash flow | $11.8B | $17.6B |
| Equity | $48.7B | $46.1B |
| Net debt / equity | 0.49× | 0.37× |
| Current ratio | 0.94× | 1.12× |
| Revenue CAGR 5y | 17.2% | 2.3% |
| Profit CAGR 5y | 26.2% | 11.6% |
AZN and NVS book revenue within 15% of each other, and NVS keeps more of each dollar of revenue as profit (25.6% against 17.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | AZN | NVS |
|---|---|---|
| FY2025 | $58.7B | $54.5B |
| FY2024 | $54.1B | $50.3B |
| FY2023 | $45.8B | $45.4B |
| FY2022 | $44.4B | $42.2B |
| FY2021 | $37.4B | $42.8B |
| FY2020 | $26.6B | $48.7B |
| FY2019 | $24.4B | $47.5B |
| FY2018 | $22.1B | $44.8B |
| FY2017 | $22.5B | $42.4B |
| FY2016 | $23.0B | $48.5B |
Net income by year
Bottom line
| Fiscal year | AZN | NVS |
|---|---|---|
| FY2025 | $10.2B | $14.0B |
| FY2024 | $7.0B | $11.9B |
| FY2023 | $6.0B | $14.8B |
| FY2022 | $3.3B | $7.0B |
| FY2021 | $112.0M | $24.0B |
| FY2020 | $3.2B | $8.1B |
| FY2019 | $1.3B | $11.7B |
| FY2018 | $2.2B | $12.6B |
| FY2017 | $3.0B | $7.7B |
| FY2016 | $3.5B | $6.7B |
Advertisement
AdSense · Rectangle 336×280